Rapport Therapeutics has seen a sharp pullback recently, and that slump puts fresh focus on whether the current share price ...

Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 ...

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results ...

Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.

Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...

Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...

Customers, whether individual consumers or major multinational clients, generally prefer to do business with companies with which they have a good relationship. Companies that have earned good reviews ...

Building rapport is a concept that is vital to sales and effective team building. But as a concept, it can be hard to understand because we tend to focus on the wrong parts of what we think are ...

Shares of Rapport Therapeutics (RAPP) catapulted on Monday after the biotech company's experimental drug significantly reduced seizures in patients with a hard-to-treat form of epilepsy. The company ...

Rapport is vital for fostering and maintaining social and business relationships. Nonverbal rapport building techniques have been extensively discussed and researched. However, the nonverbal cues that ...

President, Sales Xceleration, leading the organization which focuses on helping small to mid-size businesses get their sales back on track. At its core, selling is about turning leads into prospects ...